2018
DOI: 10.14715/cmb/2018.64.13.7
|View full text |Cite
|
Sign up to set email alerts
|

A meta-analysis of association between serum iron levels and lung cancer risk

Abstract: Many studies conducted on the relationship between serum iron levels and lung cancer risk had produced inconsistent results. We therefore conducted a meta-analysis to determine whether serum iron levels were lower in lung cancer patients compared to those in controls.A literature survey was conducted by searching the PubMed, WanFang, CNKI, and SinoMed databases for articles published as of Mar 1, 2018. Standard mean differences (SMD) with the corresponding 95% confidence intervals (CI) were executed by Stata 1… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
9
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 14 publications
(9 citation statements)
references
References 12 publications
0
9
0
Order By: Relevance
“…Some previous studies had been published to explore serum element levels and lung cancer risk. Chen et al performed a meta-analysis with 13 publications to assess the association between serum iron levels and lung cancer risk [48]. The authors concluded that serum iron levels had no effect on the risk of lung cancer.…”
Section: Discussionmentioning
confidence: 99%
“…Some previous studies had been published to explore serum element levels and lung cancer risk. Chen et al performed a meta-analysis with 13 publications to assess the association between serum iron levels and lung cancer risk [48]. The authors concluded that serum iron levels had no effect on the risk of lung cancer.…”
Section: Discussionmentioning
confidence: 99%
“…A randomized trial of 1277 individuals with peripheral arterial disease (636 in iron reduction group through venesection and 641 in control group) found that in the iron reduction group, who received regular phlebotomy, the risk of overall cancer, cancer-specific mortality and all-cause mortality was lower than in the control group after 4.5 years of follow-up [4]. However, findings of observational studies are inconsistent or scarce concerning the effects of iron status on individual cancers, such as colorectal, breast and oesophagal cancer [5][6][7][8][9][10][11]. Consequently, whether iron status (which is routinely measured in clinical practice as serum iron, transferrin saturation, ferritin and transferrin) plays a role in the development of site-specific cancer remains inconclusive.…”
Section: Introductionmentioning
confidence: 99%
“…Transferrin saturation also exceeded 20−50%, the limit commonly used to diagnose iron overload (Elsayed et al, 2016;Sebastiani et al, 2012). In addition to being a consequence of disorders related to iron metabolism or recurrent blood transfusions, an elevated serum iron level is also considered a risk factor for increased mortality in patients with sepsis (Lan et al, 2018), pre-eclampsia in pregnant women (Liu et al, 2019) and several types of cancers, such as liver, lung and breast (Chen et al, 2018;Wen et al, 2014). In this regard, the present experimental animal model of parenteral administration is commonly used to simulate a chronic state of iron overload in humans, regardless of the aetiology.…”
Section: Discussionmentioning
confidence: 99%